Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 2.54 below Alpha Teknova Inc 's average Quick Ratio.

Within In Vitro & In Vivo Diagnostic Substances industry 4 other companies have achieved higher Quick Ratio than Alpha Teknova Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1079 to 1225.

Explain Quick Ratio?
How much Cash & cash equivalents TKNO�s has?
What are TKNO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TKNO Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	6.08 %	-2.11 %	-32.77 %	-48.01 %	-12.61 %
Y / Y Cash & cash equivalent Change	-27.35 %	-32.31 %	-29.8 %	-30.21 %	29.06 %
Quick Ratio MRQ	2.54	2.58	2.83	4.38	3.7
TKNO's Total Ranking	# 1225	# 1079	# 967	# 658	#
Seq. Current Liabilities Change	-0.35 %	-8.5 %	49.16 %	-22 %	-8.05 %
Seq. Cash & cash equivalent Change	-1.96 %	-16.66 %	-3.52 %	-7.85 %	-8.65 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 5
Healthcare Sector	# 440
Overall Market	# 1225

Quick Ratio Statistics
High	Average	Low
4.38	2.89	0.83
(Sep 30 2025)		(Jun 30 2023)

Financial Statements
Alpha Teknova Inc 's Current Liabilities	$ 7 Millions	Visit TKNO's Balance sheet
Alpha Teknova Inc 's Cash & cash equivalent	$ 17 Millions	Visit TKNO's Balance sheet
Source of TKNO's Sales		Visit TKNO's Sales by Geography

Cumulative Alpha Teknova Inc 's Quick Ratio

TKNO's Quick Ratio for the trailling 12 Months

TKNO Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-23.5 %	-26.63 %	-26.2 %	-9.86 %	8.8 %
Y / Y Cash & cash equivalent TTM Growth	-29.98 %	-20.31 %	-8.36 %	2.41 %	11.52 %
Quick Ratio TTM	2.98	3.28	3.59	3.45	3.26
Total Ranking TTM	# 3829	# 3810	# 2943	# 3052	#
Seq. Current Liabilities TTM Growth	1.52 %	-0.57 %	-12.33 %	-13.54 %	-2.64 %
Seq. Cash & cash equivalent TTM Growth	-7.7 %	-9.06 %	-8.81 %	-8.52 %	5.05 %

Quick ratio ranking by company, industry and sector >> Back to TKNO Financial Strength Comparisons >> Go to Compare TKNO Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q2 2026 to $6.87 millions, cumulative Quick Ratio decreased to 2.98 above the TKNO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Alpha Teknova Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3810 to 3829.

Explain Quick Ratio?
How much Cash & cash equivalents TKNO�s has?
What are TKNO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 880
Within the Market	# 3829

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.35	2.52	0.39
(Dec 31 2025)		(Jun 30 2023)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Intellia Therapeutics Inc	5.51	$ 437.759 Millions	$ 79.392 Millions
Qc Technologies Inc	3.00	$ 10.987 Millions	$ 3.669 Millions
Alpha Teknova Inc	2.54	$ 17.436 Millions	$ 6.872 Millions
Lantheus Holdings Inc	1.77	$ 593.298 Millions	$ 335.677 Millions
Insight Molecular Diagnostics Inc	1.73	$ 17.756 Millions	$ 10.286 Millions
Achieve Life Sciences Inc	1.65	$ 326.645 Millions	$ 197.657 Millions
Immucell Corporation	1.51	$ 8.860 Millions	$ 5.863 Millions
Myriad Genetics Inc	0.88	$ 115.200 Millions	$ 130.700 Millions
Biomerica Inc	0.53	$ 1.308 Millions	$ 2.481 Millions

Date modified: 2026-09-08T01:26:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.